Abstract :

Small-cell lung cancer (SCLC) accounts for roughly 15% of all lung malignancies and is distinguished by a high proliferative rate, a proclivity for early metastasis, and a poor prognosis. Exposure to cigarette carcinogens is highly linked to SCLC. Only one-third of individuals have earlier-stage illness that is responsive to possibly curative multimodality treatment at the time of diagnosis. SCLC genomic analysis revealed a high mutation load and widespread chromosomal rearrangements, nearly usually with functional inactivation of the tumour suppressor genes TP53 and RB1. The relative expression of prominent transcriptional regulators has been used to identify subtypes of illness in both human SCLC and murine models, revealing significant intra-tumoural variation. Tumor development, metastasis, and acquired treatment resistance have been linked to aspects of this heterogeneity. Despite the fact that clinical progress in the treatment of SCLC has been notoriously poor, a greater knowledge of the biology of the disease has revealed new vulnerabilities that might be targeted therapeutically. Immune checkpoint blockade, which was recently introduced into the treatment of SCLC patients, has given benefit to patients, with a small fraction of patients experiencing long-term benefits. Strategies to focus tailored therapy to the patients most likely to react and to extend the long-term benefits of successful anti-tumor immunity to a larger number of patients are urgently needed and are now being researched.

---

Keywords :

Adenocarcinoma; Circulating tumour cells (CTCs); Small-cell lung cancer (SCLC); Tumour suppressor genes.

---

References :

1. Hann CL, Wu MA, Rekhtman N &Rudin CM in Cancer Principles & Practice of Oncology Ch. 49(edsDeVita VT, Lawrence TS & Rosenberg SA) 671–700 (Wolters Kluwer, 2019).
2. Hou JM et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.  Clin. Oncol30, 525–532 (2012).
3. Kalemkerian GP et al. NCCN guidelines insights: small cell lung cancer, version 2.2018.  NatlCompr. CancNetw16, 1171–1182 (2018).
4. Bray F et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin68, 394–424 (2018).
5. International Agency for Research on Cancer. Cancer Incidence in Five Continents Volume X(IARC, 2014).
6. Francisci S et al. Survival patterns in lung and pleural cancer in Europe 1999–2007: Results from the EUROCARE-5 study.  J. Cancer51, 2242–2253 (2015).
7. Govindan R et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.  Clin. Oncol24, 4539–4544 (2006).
8. Breitling LP, RinkeA&Gress TM Recent survival trends in high-grade neuroendocrine neoplasms and lung cancer. Neuroendocrinology110, 225–233 (2020).
9. Abdel-Rahman O Changing epidemiology of elderly small cell lung cancer patients over the last 40 years; a SEER database analysis.  Respir. J12, 1093–1099 (2018).
10. American Lung Association. Tobacco use in racial and ethnic populationsAmerican Lung Association; https://www.lung.org/stop-smoking/smoking-facts/tobacco-use-racial-and-ethnic.html (2020).
11. American Cancer Society. Cancer facts & figures 2019(ACS, 2019).
12. Huang R et al. Associated links among smoking, chronic obstructive pulmonary disease, and small cell lung cancer: a pooled analysis in the International Lung Cancer Consortium. EBioMedicine2, 1677–1685 (2015).
13. Varghese AM et al. Small-cell lung cancers in patients who never smoked cigarettes.  Thorac. Oncol9, 892–896 (2014).
14. Lamichhane DK et al. Lung cancer risk and residential exposure to air pollution: a korean population-based case-control study. Yonsei Med. J58, 1111–1118 (2017).
15. Rodriguez-Martinez A, Torres-Duran M, Barros-Dios JM &Ruano-RavinaA Residential radon and small cell lung cancer. A systematic review. Cancer Lett426, 57–62 (2018).
16. Wang J et al. Genetic predisposition to lung cancer: comprehensive literature integration, meta-analysis, and multiple evidence assessment of candidate-gene association studies.  Rep7, 8371 (2017).
17. Improgo MR, Scofield MD, Tapper AR & Gardner PD From smoking to lung cancer: the CHRNA5/A3/B4 connection. Oncogene29, 4874–4884 (2010).
18. Quintanal-VillalongaA et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance.  Rev. Clin. Oncol17, 360–371 (2020).
19. Aarts MJ et al. Comorbidity in patients with small-cell lung cancer: trends and prognostic impact.  Lung Cancer16, 282–291 (2015).
20. Seigneurin A et al. Are comorbidities associated with long-term survival of lung cancer? A population-based cohort study from French cancer registries. BMC Cancer18, 1091 (2018).
21. Wang S et al. Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages.  Rep7, 1339 (2017).
22. National Lung Screening Trial Research Team. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening.  Engl. J. Med365, 395–409 (2011).
23. Thomas A, Pattanayak P, Szabo E &Pinsky P Characteristics and outcomes of small cell lung cancer detected by CT screening. Chest154, 1284–1290 (2018).
24. George J et al. Comprehensive genomic profiles of small cell lung cancer. Nature524, 47–53 (2015).
25. Harbour JW et al. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science241, 353–357 (1988).
26. Wistuba II, Gazdar AF &Minna JD Molecular genetics of small cell lung carcinoma.  Oncol28 (Suppl. 4), 3–13 (2001).
27. Little CD, Nau MM, Carney DN, Gazdar AF &Minna JD Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature306, 194–196 (1983).
28. Nau MM et al. Amplification, expression and rearrangement of c-myc and N-myc oncogenes in human lung cancer.  Top. Microbiol. Immunol113, 172–177 (1984).
29. Nau MM et al. L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature318, 69–73 (1985).
30. Peifer M et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.  Genet44, 1104–1110 (2012).
31. Rudin CM et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.  Genet44, 1111–1116 (2012).
32. Drapkin BJ et al. Genomic and functional fidelity of small cell lung cancer patient-derived xenografts. Cancer Discov8, 600–615 (2018).
33. Udagawa H et al. Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis. Lung Cancer126, 182–188 (2018).
34. Schaffer BE et al. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res70, 3877–3883 (2010).
35. Lazaro S et al. Differential development of large-cell neuroendocrine or small-cell lung carcinoma upon inactivation of 4 tumor suppressor genes.  Natl Acad. Sci. USA116, 22300–22306 (2019).
36. Ng SR et al. CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer.  Natl Acad. Sci. USA117, 513–521 (2020).
37. McFadden DG et al. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell156, 1298–1311 (2014).
38. Cui M et al. PTEN is a potent suppressor of small cell lung cancer.  Cancer Res12, 654–659 (2014).
39. Lim JS et al. Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer. Nature545, 360–364 (2017).
40. Augert A et al. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.  Signal12, eaau2922 (2019).
41. Jia D et al. Crebbp loss drives small cell lung cancer and increases sensitivity to HDAC inhibition. Cancer Discov8, 1422–1437 (2018).
42. Bottger F et al. Tumor heterogeneity underlies differential cisplatin sensitivity in mouse models of small-cell lung cancer. Cell Rep27, 3345–3358.e4 (2019).
43. Kim DW et al. Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer. Genes Dev30, 1289–1299 (2016).
44. Mollaoglu G et al. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition. Cancer Cell31, 270–285 (2017).
45. Ferone G et al. FGFR1 oncogenic activation reveals an alternative cell of origin of SCLC in Rb1/p53 Mice. Cell Rep30, 3837–3850.e3 (2020).
46. Coles GL et al. Unbiased proteomic profiling uncovers a targetable GNAS/PKA/PP2A axis in small cell lung cancer stem cells. Cancer Cell38, 129–143. e7 (2020).
47. AugertA et al. Small cell lung cancer exhibits frequent inactivating mutations in the histone methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).  Thorac. Oncol12, 704–713 (2017).
48. Wagner AH et al. Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer.  Commun9, 3787 (2018).
49. Zhou F & Zhou C Lung cancer in never smokers — the East Asian experience.  Lung Cancer Res7, 450 (2018).
50. Niederst MJ et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.  Commun6, 6377 (2015).
51. Popat S Histologically transformed SCLC from EGFR-mutant NSCLC: understanding the wolf in sheep’s clothing.  Thorac. Oncol14, 1689–1691 (2019).
52. Offin M et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes.  Thorac. Oncol14, 1784–1793 (2019).
53. Hodgkinson CL et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer.  Med20, 897–903 (2014).
54. Meuwissen R et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell4, 181–189 (2003).
55. Gazdar AF et al. The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung.  Thorac. Oncol10, 553–564 (2015).
56. Ferone G, Lee MC, Sage J &BernsA Cells of origin of lung cancers: lessons from mouse studies. Genes Dev34, 1017–1032 (2020).
57. Ben-Ezra JM, Kornstein MJ, Grimes MM & Krystal G Small cell carcinomas of the lung express the Bcl-2 protein.  J. Pathol145, 1036–1040 (1994).
58. Ikegaki N, Katsumata M, Minna J &Tsujimoto Y Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res54, 6–8 (1994).
59. Lochmann TL et al. Venetoclax is effective in small-cell lung cancers with high BCL-2 expression.  Cancer Res24, 360–369 (2018).
60. Doerr F et al. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.  Rep7, 15511 (2017).
61. Sen T et al. CHK1 inhibition in small-cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib. Cancer Res77, 3870–3884 (2017).
62. Sen T et al. Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small-cell lung cancer.  Cancer Res23, 6239–6253 (2017).
63. Hsu WH et al. Checkpoint kinase 1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in SCLC by promoting mitotic cell death.  Thorac. Oncol14, 1032–1045 (2019).
64. Oser MG et al. Cells lacking the RB1 tumor suppressor gene are hyperdependent on aurora B kinase for survival. Cancer Discov9, 230–247 (2019).
65. Owonikoko TK et al. Randomized phase II study of paclitaxel plus alisertib versus paclitaxel plus placebo as second-line therapy for SCLC: primary and correlative biomarker analyses.  Thorac. Oncol15, 274–287 (2020).
66. Byers LA et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov2, 798–811 (2012).
67. Lallo A et al. The combination of the PARP inhibitor olaparib and the WEE1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer.  Cancer Res24, 5153–5164 (2018).
68. Sen T et al. Targeting DNA damage response promotes anti-tumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov9, 646–661 (2019).
69. Gardner EE et al. Rapamycin rescues ABT-737 efficacy in small cell lung cancer. Cancer Res74, 2846–2856 (2014).
70. Faber AC et al. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.  Natl Acad. Sci. USA112, E1288–E1296 (2015).
71. Dick FA, Goodrich DW, Sage J & Dyson NJ Non-canonical functions of the RB protein in cancer.  Rev. Cancer18, 442–451 (2018).
72. Levine AJ, Puzio-Kuter AM, Chan CS & Hainaut P The role of the p53 protein in stem-cell biology and epigenetic regulation. Cold Spring Harb. Perspect. Med6, a026153 (2016).
73. Ku SY et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science355, 78–83 (2017).
74. Mu P et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science355, 84–88 (2017).
75. Kareta MS et al. Inhibition of pluripotency networks by the Rb tumor suppressor restricts reprogramming and tumorigenesis. Cell Stem Cell16, 39–50 (2015).
76. Mohammad HP et al. A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell28, 57–69 (2015).
77. Gardner EE et al. Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis. Cancer Cell31, 286–299 (2017).
78. Stewart CA et al. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer.  Cancer1, 423–436 (2020).
79. Simpson KL et al. A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity.  Cancer1, 437–451 (2020).
80. Ouadah Y et al. Rare pulmonary neuroendocrine cells are stem cells regulated by Rb, p53, and Notch. Cell179, 403–416.e23 (2019).
81. Park KS et al. Characterization of the cell of origin for small cell lung cancer. Cell Cycle10, 2806–2815 (2011).
82. Sutherland KD et al. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell19, 754–764 (2011).
83. Yang D et al. Intertumoral heterogeneity in SCLC is influenced by the cell type of origin. Cancer Discov8, 1316–1331 (2018).
84. Kuo CS &Krasnow MA Formation of a neurosensory organ by epithelial cell slithering. Cell163, 394–405 (2015).
85. Fridman R et al. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines.  Natl Acad. Sci. USA87, 6698–6702 (1990).
86. Burger M et al. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene22, 8093–8101 (2003).
87. Hartmann TN, Burger JA, Glodek A, Fujii N & Burger M CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene24, 4462–4471 (2005).
88. Burger JA, Stewart DJ, Wald O &PeledA Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev. Anticancer. Ther11, 621–630 (2011).
89. Guo N et al. Thrombospondin-1 promotes alpha3beta1 integrin-mediated adhesion and neurite-like outgrowth and inhibits proliferation of small cell lung carcinoma cells. Cancer Res60, 457–466 (2000).
90. Yang D et al. Axon-like protrusions promote small cell lung cancer migration and metastasis. eLife8, e50616 (2019).
91. Allison Stewart C et al. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget8, 28575–28587 (2017).
92. Canadas I et al. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.  Cancer Res20, 938–950 (2014).
93. Cattaneo MG, Codignola A, Vicentini LM, Clementi F &Sher E Nicotine stimulates a serotonergic autocrine loop in human small-cell lung carcinoma. Cancer Res53, 5566–5568 (1993).
94. Heasley LE Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene20, 1563–1569 (2001).
95. Song P et al. M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Cancer Res67, 3936–3944 (2007).
96. Jahchan NS et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov3, 1364–1377 (2013).
97. Park KS et al. A crucial requirement for Hedgehog signaling in small cell lung cancer.  Med17, 1504–1508 (2011).
98. Krystal GW, Hines SJ & Organ CP Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res56, 370–376 (1996).
99. Nakanishi Y et al. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro.  Clin. Invest82, 354–359 (1988).
100. Kwon MC et al. Paracrine signaling between tumor subclones of mouse SCLC: a critical role of ETS transcription factor Pea3 in facilitating metastasis. Genes Dev29, 1587–1592 (2015).
101. Vanhees SL, Paridaens R &Vansteenkiste JF Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumourlysis in small-cell lung cancer: case report and literature review.  Oncol11, 1061–1065 (2000).
102. Kanaji N et al. Paraneoplastic syndromes associated with lung cancer. World J. Clin. Oncol5, 197–223 (2014).
103. Nomura M, Morita M &Tanuma N A metabolic vulnerability of small-cell lung cancer. Oncotarget9, 32278–32279 (2018).
104. Staal-van den Brekel AJ et al. Metabolism in patients with small cell lung carcinoma compared with patients with non-small cell lung carcinoma and healthy controls. Thorax52, 338–341 (1997).
105. Cristea S et al. The MEK5-ERK5 kinase axis controls lipid metabolism in small cell lung cancer. Cancer Res80, 1293–1303 (2020).
106. Umemura S et al. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.  Thorac. Oncol9, 1324–1331 (2014).
107. Chalishazar MD et al. MYC-driven small-cell lung cancer is metabolically distinct and vulnerable to arginine depletion.  Cancer Res25, 5107–5121 (2019).
108. Carter L et al. Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer.  Med23, 114–119 (2017).
109. Simpson KL et al. A biobank of small cell lung cancer CDX models elucidates inter-and intratumoral phenotypic heterogeneity.  Cancer1, 437–451 (2020).
110. Stewart CA et al. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer.  Cancer1, 423–436 (2020).
111. Niho S et al. Detection of unsuspected distant metastases and/or regional nodes by FDG-PET in LD-SCLC scan in apparent limited-disease small-cell lung cancer. Lung Cancer57, 328–333 (2007).
112. Denny SK et al. Nfib promotes metastasis through a widespread increase in chromatin accessibility. Cell166, 328–342 (2016).
113. Semenova EA et al. Transcription factor NFIB is a driver of small cell lung cancer progression in mice and marks metastatic disease in patients. Cell Rep16, 631–643 (2016).
114. Wu N et al. NFIB overexpression cooperates with Rb/p53 deletion to promote small cell lung cancer. Oncotarget7, 57514–57524 (2016).
115. Yang D et al. Axon-like protrusions promote small cell lung cancer migration and metastasis. eLife8, e50616 (2019).
116. Iams WT et al. Improved prognosis and increased tumor-infiltrating lymphocytes in patients who have SCLC with neurologic paraneoplastic syndromes.  Thorac. Oncol14, 1970–1981 (2019).
117. Antonia SJ et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol17, 883–895 (2016).
118. Ready NE et al. Nivolumabmonotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the checkmate 032 randomized cohort.  Thorac. Oncol15, 426–435 (2020).
119. Ready NE et al. Nivolumabmonotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the checkmate 032 randomized cohort.  Thorac. Oncol15, 426–435 (2020).
120. Chung HC et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies.  Thorac. Oncol15, 618–627 (2020).
121. Doyle A et al. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer.  Exp. Med161, 1135–1151 (1985).
122. Yazawa T et al. Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer.  Pathol187, 191–199 (1999).
123. Funa K, Gazdar AF, Minna JD &Linnoila RI Paucity of beta 2-microglobulin expression on small cell lung cancer, bronchial carcinoids and certain other neuroendocrine tumors.  Invest55, 186–193 (1986).
124. Traversari C et al. IFN-gamma gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer. Gene Ther4, 1029–1035 (1997).
125. Wang W et al. Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate.  J. Cancer131, E928–E937 (2012).
126. Eerola AK, Soini Y &Paakko P A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma.  Cancer Res6, 1875–1881 (2000).
127. Makarenkova VP et al. Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells.  Neuroimmunol145, 55–67 (2003).
128. Weiskopf K et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.  Clin. Invest126, 2610–2620 (2016).
129. Owen DH et al. DLL3: an emerging target in small cell lung cancer.  Hematol. Oncol12, 61 (2019).
130. Rudin CM et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.  Rev. Cancer19, 289–297 (2019).
131. Wooten DJ et al. Systems-level network modeling of small cell lung cancer subtypes identifies master regulators and destabilizers.  Biol15, e1007343 (2019).
132. Sos ML et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer.  Natl Acad. Sci. USA109, 17034–17039 (2012).
133. Owonikoko TK et al. Randomized phase II study of paclitaxel plus alisertib versus paclitaxel plus placebo as second-line therapy for small-cell lung cancer: primary and correlative biomarker analyses.  Thorac. Oncol15, 274–287 (2020).
134. Ireland AS et al. MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate. Cancer Cell38, 60–78.e12 (2020).
135. Travis WD et al. The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification.  Thorac. Oncol10, 1243–1260 (2015).
136. vanMeerbeeck JP, Fennell DA & De Ruysscher DK Small-cell lung cancer. Lancet378, 1741–1755 (2011).
137. Horn L et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer.  Engl. J. Med379, 2220–2229 (2018).
138. Paz-Ares L et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet394, 1929–1939 (2019).
139. Rudin CM et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study.  Clin. Oncol38, 2369–2379 (2020).
140. Fruh M et al. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up.  Oncol24, vi99–vi105 (2013).
141. Tay RY et al. Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.  Oncol30, 1114–1120 (2019).
142. Stovold R et al. Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells. Lung Cancer76, 263–268 (2012).
143. Fernandez-Cuesta L et al. Identification of circulating tumor DNA for the early detection of small-cell lung cancer. EBioMedicine10, 117–123 (2016).
144. Almodovar K et al. Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse.  Thorac. Oncol13, 112–123 (2018).
145. Travis WD Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine.  Surg. Clin24, 257–266 (2014).
146. Austin JH et al. Small-cell carcinoma of the lung detected by CT screening: stage distribution and curability. Lung Cancer76, 339–343 (2012).
147. Nicholson AG et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer.  Thorac. Oncol11, 300–311 (2016).
148. Davis S, Stanley KE, Yesner R, Kuang DT & Morris JF Small-cell carcinoma of the lung–survival according to histologic subtype: a Veterans Administration Lung Group Study. Cancer47, 1863–1866 (1981).
149. Shepherd FA et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer.  Thorac. Oncol2, 1067–1077 (2007).
150. Vallieres E et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer.  Thorac. Oncol4, 1049–1059 (2009).
151. Hochstenbag MM, Twijnstra A, Wilmink JT, Wouters EF & ten Velde GP Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis.  Neurooncol48, 243–248 (2000).
152. Nicholson SA et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens.  J. Surg. Pathol26, 1184–1197 (2002).
153. Travis WD Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas.  Pathol25(Suppl. 1), S18–S30 (2012).
154. Mangum MD, Greco FA, Hainsworth JD, Hande KR & Johnson DH Combined small-cell and non-small-cell lung cancer.  Clin. Oncol7, 607–612 (1989).
155. Baine MK et al. Small cell lung carcinoma subtypes defined by ASCL1, NEUROD1, POU2F3 and YAP1: comprehensive immunohistochemical and histopathologic characterization.  Thorac. Oncol15, 1823–1835 (2020).
156. Brambilla E et al. Cytotoxic chemotherapy induces cell differentiation in small-cell lung carcinoma.  Clin. Oncol9, 50–61 (1991).
157. Sehested M, Hirsch FR, Osterlind K & Olsen JE Morphologic variations of small cell lung cancer. A histopathologic study of pretreatment and posttreatment specimens in 104 patients. Cancer57, 804–807 (1986).
158. Pelosi G et al. Classification of pulmonary neuroendocrine tumors: new insights.  Lung Cancer Res6, 513–529 (2017).
159. Kriegsmann K et al. Insulinoma-associated protein 1 (INSM1) in thoracic tumors is less sensitive but more specific compared with synaptophysin, chromogranin A, and CD56.  Immunohistochem. Mol. Morphol28, 237–242 (2020).
160. Mukhopadhyay S, Dermawan JK, Lanigan CP &Farver CF Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections.  Pathol32, 100–109 (2019).
161. Pelosi G, Rindi G, Travis WD &Papotti M Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice.  Thorac. Oncol9, 273–284 (2014).
162. Brambilla E et al. Basal cell (basaloid) carcinoma of the lung: a new morphologic and phenotypic entity with separate prognostic significance.  Pathol23, 993–1003 (1992).
163. Sturm N et al. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung.  Pathol32, 918–925 (2001).
164. Rekhtman N et al. Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsinA expression and genomic alterations.  Pathol31, 111–121 (2018).
165. Sturm N et al. 34BetaE12 expression along the whole spectrum of neuroendocrine proliferations of the lung, from neuroendocrine cell hyperplasia to small cell carcinoma. Histopathology42, 156–166 (2003).
166. Cheuk W, Kwan MY, Suster S & Chan JK Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas.  Pathol. Lab. Med125, 228–231 (2001).
167. Devoe K & Weidner N Immunohistochemistry of small round-cell tumors.  Diagn. Pathol17, 216–224 (2000).
168. Marino-Enriquez A& Fletcher CD Round cell sarcomas — biologically important refinements in subclassification.  J. Biochem. Cell Biol53, 493–504 (2014).
169. Creytens D SATB2 and TLE1 Expression in BCOR-CCNB3 (Ewing-like) sarcoma, mimicking small cell osteosarcoma and poorly differentiated synovial sarcoma.  Immunohistochem. Mol. Morphol28, e10–e12 (2020).
170. Rekhtman N et al. SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas.  Thorac. Oncol15, 231–247 (2020).
171. Aberle DR et al. Results of the two incidence screenings in the National Lung Screening Trial.  Engl. J. Med369, 920–931 (2013).
172. Silva M et al. Screening with low-dose computed tomography does not improve survival of small cell lung cancer.  Thorac. Oncol11, 187–193 (2016).
173. Cuffe S et al. Characteristics and outcomes of small cell lung cancer patients diagnosed during two lung cancer computed tomographic screening programs in heavy smokers.  Thorac. Oncol6, 818–822 (2011).
174. deKoning HJ et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial.  Engl. J. Med382, 503–513 (2020).
175. Harmsma M, Schutte B &Ramaekers FC Serum markers in small cell lung cancer: opportunities for improvement.  Biophys. Acta1836, 255–272 (2013).
176. Parsons A, Daley A, Begh R &Aveyard P Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ340, b5569 (2010).
177. Karam I, Jiang SY, Khaira M, Lee CW &Schellenberg D Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide.  J. Clin. Oncol38, 51–54 (2015).
178. Kubota K et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Lancet Oncol15, 106–113 (2014).
179. Antonia SJ et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC.  Engl. J. Med379, 2342–2350 (2018).
180. AuperinA et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic cranial irradiation overview collaborative group.  Engl. J. Med341, 476–484 (1999).
181. Wakeam E et al. Surgery versus chemotherapy and radiotherapy for early and locally advanced small cell lung cancer: a propensity-matched analysis of survival. Lung Cancer109, 78–88 (2017).
182. Lad T et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest106, 320S–323S (1994).
183. Fox W &Scadding JG Medical research council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet2, 63–65 (1973).
184. Barnes H, See K, Barnett S &Manser R Surgery for limited-stage small-cell lung cancer. Cochrane Database Syst. Rev4, CD011917 (2017).
185. Zhao H, Ren D, Liu H & Chen J Comparison and discussion of the treatment guidelines for small cell lung cancer.  Cancer9, 769–774 (2018).
186. Quoix E, Fraser R, Wolkove N, Finkelstein H &Kreisman H Small cell lung cancer presenting as a solitary pulmonary nodule. Cancer66, 577–582 (1990).
187. Rami-Porta R, Wittekind C &Goldstraw P, International Association for the Study of Lung Cancer (IASLC) Staging Committee. Complete resection in lung cancer surgery: proposed definition. Lung Cancer49, 25–33 (2005).
188. Yang CF et al. Role of adjuvant therapy in a population-based cohort of patients with early-stage small-cell lung cancer.  Clin. Oncol34, 1057–1064 (2016).
189. Brock MV et al. Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come.  Thorac. Cardiovasc. Surg129, 64–72 (2005).
190. Salem A et al. Association of chemoradiotherapy with outcomes among patients with stage I to II vs stage III small cell lung cancer: secondary analysis of a randomized clinical trial. JAMA Oncol5, e185335 (2019).
191. Simone CB II et al. Radiation therapy for small cell lung cancer: An ASTRO clinical practice guideline.  Radiat. Oncol10, 158–173 (2020).
192. Verma V et al. Multi-institutional experience of stereotactic ablative radiation therapy for stage I small cell lung cancer.  J. Radiat. Oncol. Biol. Phys97, 362–371 (2017).
193. Wu AJ et al. Patterns of failure in limited-stage small cell lung cancer: Implications of TNM stage for prophylactic cranial irradiation.  Oncol125, 130–135 (2017).
194. Yang Y et al. Prophylactic cranial irradiation in resected small cell lung cancer: a systematic review with meta-analysis.  Cancer9, 433–439 (2018).
195. Zhu H et al. Prophylactic cranial irradiation improved the overall survival of patients with surgically resected small cell lung cancer, but not for stage I disease. Lung Cancer86, 334–338 (2014).
196. Pignon JP et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer.  Engl. J. Med327, 1618–1624 (1992).
197. Faivre-Finn C et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol18, 1116–1125 (2017).
198. Turrisi AT III et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.  Engl. J. Med340, 265–271 (1999).
199. Levy A et al. Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey. Lung Cancer136, 145–147 (2019).
200. De Ruysscher D et al. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer.  Oncol17, 543–552 (2006).
201. Fried DB et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer.  Clin. Oncol22, 4837–4845 (2004).
202. Huncharek M &McGarry R A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist9, 665–672 (2004).
203. Pijls-Johannesma MC, De Ruysscher D, Lambin P, Rutten I &Vansteenkiste JF Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst. Rev1, CD004700 (2005).
204. Sun JM et al. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer.  Oncol24, 2088–2092 (2013).
205. Christodoulou M et al. Compliance and outcome of elderly patients treated in the concurrent once-daily versus twice-daily radiotherapy (CONVERT) Trial.  Thorac. Oncol14, 63–71 (2019).
206. Hu X et al. Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses. Cancer126, 840–849 (2020).
207. Le Pechoux C et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99–01, EORTC 22003–08004, RTOG 0212, and IFCT 99–01): a randomised clinical trial. Lancet Oncol10, 467–474 (2009).
208. Eaton BR et al. Effect of prophylactic cranial irradiation on survival in elderly patients with limited-stage small cell lung cancer. Cancer119, 3753–3760 (2013).
209. Noda K et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.  Engl. J. Med346, 85–91 (2002).
210. Lara PN Jr. et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.  Clin. Oncol27, 2530–2535 (2009).
211. Hanna N et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.  Clin. Oncol24, 2038–2043 (2006).
212. Hellmann MD et al. Tumor mutational burden and efficacy of nivolumabmonotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell35, 329 (2019).
213. Trigo J et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol21, 645–654 (2020).
214. Slotman B et al. Prophylactic cranial irradiation in extensive small-cell lung cancer.  Engl. J. Med357, 664–672 (2007).
215. Takahashi T et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol18, 663–671 (2017).
216. Rusthoven CG & Kavanagh BD Prophylactic cranial irradiation (PCI) versus active MRI surveillance for small cell lung cancer: the case for equipoise.  Thorac. Oncol12, 1746–1754 (2017).
217. Slotman BJ et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet385, 36–42 (2015).
218. Sagman U et al. Second primary malignancies following diagnosis of small-cell lung cancer.  Clin. Oncol10, 1525–1533 (1992).
219. Kono M et al. Incidence of second malignancy after successful treatment of limited-stage small-cell lung cancer and its effects on survival.  Thorac. Oncol12, 1696–1703 (2017).
220. Verma V et al. Cardiac mortality in limited-stage small cell lung cancer.  Oncol128, 492–497 (2018).
221. Ferris MJ et al. Radiation therapy is associated with an increased incidence of cardiac events in patients with small cell lung cancer.  J. Radiat. Oncol. Biol. Phys102, 383–390 (2018).
222. Richardson GE et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers.  Intern. Med119, 383–390 (1993).
223. Giuliani M et al. Utilization of prophylactic cranial irradiation in patients with limited stage small cell lung carcinoma. Cancer116, 5694–5699 (2010).
224. Grosshans DR, Meyers CA, Allen PK, Davenport SD & Komaki R Neurocognitive function in patients with small cell lung cancer: effect of prophylactic cranial irradiation. Cancer112, 589–595 (2008).
225. Drapkin BJ &Rudin CM Advances in small-cell lung cancer (SCLC) translational research. Cold Spring Harb. Perspect. Med1101/cshperspect.a038240 (2020).
226. Taguchi A et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell20, 289–299 (2011).
227. Huang YH et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev32, 915–928 (2018).
228. Calbo J et al. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell19, 244–256 (2011).
229. Iams WT, Porter J & Horn L Immunotherapeutic approaches for small-cell lung cancer.  Rev. Clin. Oncol17, 300–312 (2020).
230. Deng L et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity41, 843–852 (2014).
231. Reits EA et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.  Exp. Med203, 1259–1271 (2006).
232. Gupta A et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation.  Immunol189, 558–566 (2012).
233. Cheng DT et al. Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology.  Mol. Diagn17, 251–264 (2015).
234. Kern JA et al. Role of mTOR as an essential kinase in SCLC.  Thorac. Oncol15, 1522–1534 (2020).
235. Potter DS et al. Inhibition of PI3K/BMX cell survival pathway sensitizes to BH3 mimetics in SCLC.  Cancer Ther15, 1248–1260 (2016).
236. Poirier JT et al. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene34, 5869–5878 (2015).
237. Burr ML et al. An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell36, 385–401.e8 (2019).